Septerna, Inc. Common Stock (SEPN)

• Market cap: $262M
• 1 day: -1.50%
• 5 days: 14.34%
• 1 month: -6.94%
• 3 months: -65.07%
• 6 months: -72.43%
• Year to date: -72.37%
• 1 year: -72.43%
• 5 years: -72.43%
• 10 years: -72.43%
• Sector: Healthcare
• Industry: Biotechnology

About: Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.

Employees: 75

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

99.38% more ownership

Funds ownership: 0% [Q3] → 99.38% (+99.38%) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $11 86% upside
• Avg. target: $31 417% upside
• High target: $50 747% upside

2 analyst ratings

• positive: 1 50%
• neutral: 1 50%
• negative: 0 0%

Wells Fargo Derek Archila 45% 1-year accuracy 14 / 31 met price target	86% upside $11	Equal-Weight Maintained	28 Mar 2025
Cantor Fitzgerald Josh Schimmer 20% 1-year accuracy 11 / 54 met price target	747% upside $50	Overweight Reiterated	11 Feb 2025